|
PCSK9 inhibition
Are we at the limit for LDL cholesterol lowering?
The PCSK9 inhibitors are set to revolutionize the management of high cardiovascular risk patients with high LDL cholesterol levels despite current therapy. These novel treatments reduce LDL cholesterol by more than 50-60%, on top of statins. The key question, therefore, is how low LDL cholesterol should be lowered in these patients?
With the first results of outcomes trials with the PCSK9 inhibitors eagerly expected in 2017, clinicians and healthcare providers will be faced with difficult decisions about who should benefit from these highly effective treatments.
PCSK9 Forum Editor Professor John Chapman discusses the patient priorities for these highly effective PCSK9-targeted treatments, in the light of the evidence and cost constraints for healthcare budgets.
View the video
 |
|
|
|
New and updated edition of our popular therapeutic guide
A second edition of the free introductory guide: PCSK9 Inhibition - New Therapies in Cardiovascular Risk Reduction is now available on the Forum’s website. This very popular book has been updated with the latest information discussing the biology and therapeutic potential of PCSK9 inhibition.
Read online » Download now »
Forward to colleagues » |
|
 |
|
|
|
|
 |
|
|
|
Questions & Answers
Read the full answer and other questions on the PCSK9 Forum » |
|
|
For the latest updates, PCSK9 news and analysis. |
|
Hot topics, news and conference reports. |
|
For videos, interviews and webcasts from leading experts. |
|
|
|
